RecruitingPhase 2Phase 3NCT05605704

Olive Leaf Extracts in the Control of Diabet

Efficacy of a Treatment Based on Olive Leaf Extracts in the Control of Diabet

Sponsor

University of Monastir

Enrollment

500 participants

Start Date

Jan 1, 2023

Study Type

INTERVENTIONAL

Conditions

Diabetes Mellitus, Type 2

Summary

This study will be carried out in 2 emergency departments (at the exit of the emergency room) and 2 external consultations (endocrinology of the CHU FB Monastir and diabetology consultation, Jemmal hospital). Patients over 18 years of age with: -Diabets

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether olive leaf extracts can help control blood sugar levels in people with diabetes. **You may be eligible if...** - You are 18 years of age or older - You have a diagnosis of diabetes (type 1 or type 2) **You may NOT be eligible if...** - There are no specific exclusion criteria listed for this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAtherolive

The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.

DRUGPlacebo Atherolive

The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The placebo will be prescribed at a dose of 400 mg once a day for 3 months.